- Home
- FGL vs ZBIO Comparison
FGL vs ZBIO Comparison
Compare FGL & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- ZBIO
- Stock Information
- Founded
- FGL 2021
- ZBIO 2019
- Country
- FGL Malaysia
- ZBIO United States
- Employees
- FGL N/A
- ZBIO N/A
- Industry
- FGL
- ZBIO
- Sector
- FGL
- ZBIO
- Exchange
- FGL NYSE
- ZBIO NYSE
- Market Cap
- FGL 25.4M
- ZBIO 389.2M
- IPO Year
- FGL 2024
- ZBIO 2024
- Fundamental
- Price
- FGL $0.88
- ZBIO $11.18
- Analyst Decision
- FGL
- ZBIO Strong Buy
- Analyst Count
- FGL 0
- ZBIO 7
- Target Price
- FGL N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- FGL 1.3M
- ZBIO 175.9K
- Earning Date
- FGL 07-22-2025
- ZBIO 08-16-2025
- Dividend Yield
- FGL N/A
- ZBIO N/A
- EPS Growth
- FGL N/A
- ZBIO N/A
- EPS
- FGL N/A
- ZBIO N/A
- Revenue
- FGL $20,205,441.00
- ZBIO $15,000,000.00
- Revenue This Year
- FGL N/A
- ZBIO $206.00
- Revenue Next Year
- FGL N/A
- ZBIO $41.92
- P/E Ratio
- FGL N/A
- ZBIO N/A
- Revenue Growth
- FGL N/A
- ZBIO N/A
- 52 Week Low
- FGL $0.66
- ZBIO $5.83
- 52 Week High
- FGL $5.26
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- ZBIO N/A
- Support Level
- FGL N/A
- ZBIO N/A
- Resistance Level
- FGL N/A
- ZBIO N/A
- Average True Range (ATR)
- FGL 0.00
- ZBIO 0.00
- MACD
- FGL 0.00
- ZBIO 0.00
- Stochastic Oscillator
- FGL 0.00
- ZBIO 0.00
About FGL FOUNDER GROUP LTD
Founder Group Ltd is a solar solutions provider in Malaysia, offering end-to-end services for commercial and industrial sectors, as well as large-scale solar power projects, encompassing project design, engineering, and comprehensive project management. Its focus is on two key segments: large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects are utility scale solar PV power plants with installed generating capacity of 1 MWac or more. C&I projects are smaller scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their own consumption, such as factories, warehouses and commercial stores. Its revenue is derived from Malaysia.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.